Saturday, March 16, 2013

"Is poison the cure, or is the cure poison?"

Type-2 Diabetes drugs including Januvia, Byetta and Victoza are being scrutinized by U.S. regulators for a potential link to pancreatic cancer. The drugs in the class include exenatide, liraglutide, sitagliptin, saxagliptin, alogliptin and linagliptin. They mimic incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal.
Bloomberg: FDA probing Diabetes drugs for Pancreatic Cancer Risk

H/T: George Glasser, commenter on Bloomberg, for the title

No comments: